Several clinical trials have evaluated the therapeutic activities of IGF-1R monoclonal antibody in various types of cancers including breast cancer, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC)19, 20, 21. This evidence concerns the gene IGF1R and head and neck squamous cell carcinoma.